AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer
Not yet recruiting · NCT07712094 · Registry updated 2026-07-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, primitive neuroectodermal tumor | Not yet recruiting | Phase 2 | 2026-07-17 | NCT07712094 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Tianjin Medical University Cancer Institute and Hospital | 287 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baotou Cancer Hospital | Baotou | China | 3 |
| Shanxi Bethune Hospital | Taiyuan | China | 26 |
| The First People's Hospital of Horqin District, Tongliao City | Tongliao | China | 1 |
| Tianjin First Central Hospital | Tianjin | China | 2 |
| Tianjin Medical University Cancer Institute and Hospital | Tianjin | China | 36 |
| Tianjin Medical University General Hospital | Tianjin | China | 28 |
| Tianjin People's Hospital | Tianjin | China | 6 |
| Tianjin Third Central Hospital | Tianjin | China | 6 |